Technetium‐99m sestamibi scintigraphy is sensitive and specific for the staging and the follow‐up of patients with multiple myeloma: a multicentre study on 397 scans
- 18 January 2007
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (5), 729-735
- https://doi.org/10.1111/j.1365-2141.2006.06489.x
Abstract
We evaluated the additional benefit of Technetium(99)-sestamibi (99mTc-MIBI) scanning in comparison with standard X-ray techniques for multiple myeloma patients either at diagnosis or during follow-up. Between February 2001 and January 2005, 397 whole body scans were acquired. On 229 scans performed at diagnosis, 146 (64%) were positive and 81 cases have discordant X-ray results. The sensitivity of 99mTc-MIBI and X-ray were 77% and 45% respectively. As a result of 99mTc-MIBI, 40% of asymptomatic myeloma patients were up-staged. The positivity of 99mTc-MIBI correlated significantly with all of the most relevant clinical and biological parameters. Multivariate analysis selected only high reactive C protein (P = 0.0005), bone marrow infiltration (P = 0.02) and bone pain (P = 0.002) as factors affecting 99mTc-MIBI pattern. In 22 patients with solitary myeloma, 99mTc-MIBI was positive in 86% of cases and detected more disease sites than X-ray. Among 168 scans performed during follow-up, 99mTc-MIBI presented high specificity in patients showing a complete response (CR; 86%), and correlated with myeloma activity and with response to therapy. At multivariate analysis, a positive pattern correlated with bone marrow infiltration (P = 0.002) and disease status other than CR (P = 0.03). We conclude that 99mTc-MIBI scanning is an additional diagnostic tool with a high specificity for the staging and the follow-up of multiple myeloma patients.Keywords
This publication has 31 references indexed in Scilit:
- Positron emission tomography and bone metastasesSeminars in Nuclear Medicine, 2005
- Value of FDG PET in the Assessment of Patients with Multiple MyelomaAmerican Journal of Roentgenology, 2005
- Functional Imaging of Multidrug Resistant Phenotype by 99mTc-MIBI Scan in Patients with Multiple MyelomaCancer Biotherapy & Radiopharmaceuticals, 2004
- A comparison of fluorine‐18 fluoro‐deoxyglucose PET and technetium‐99m sestamibi in assessing patients with multiple myelomaEuropean Journal of Haematology, 2003
- Positron Emission Tomography (PET) for Staging of Solitary PlasmacytomaCancer Biotherapy & Radiopharmaceuticals, 2003
- Reverse of the Differential Uptake Intensity of Tc-99m MIBI and Tc-99m V-DMSA By Multiple Myeloma Lesions in Response to TherapyClinical Nuclear Medicine, 2003
- 99mTc-MIBI scintigraphy in untreated stage III multiple myeloma: comparison with X-ray skeletal survey and bone scintigraphyNuclear Medicine Communications, 2003
- Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBI scintigraphy and other biochemical markers of disease activityHematological Oncology, 2002
- Bone marrow uptake of 99mTc-MIBI in patients with multiple myelomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998